loading...| Preferred Name |
Blinatumomab |
|
| Synonyms |
BLINATUMOMAB Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody Blinatumomab Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103 AMG 103 Blincyto MEDI-538 MEDI538 MT-103 MT103 |
|
| Definitions |
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C62528 |
|
| Accepted_Therapeutic_Use_For |
relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) |
|
| CAS_Registry |
853426-35-4 |
|
| code |
C62528 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. |
|
| Display_Name |
Blinatumomab |
|
| FDA_UNII_Code |
4FR53SIF3A |
|
| FULL_SYN |
BLINATUMOMAB Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody Blinatumomab Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103 AMG 103 Blincyto MEDI-538 MEDI538 MT-103 MT103 |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Blinatumomab |
|
| Legacy Concept Name |
Anti-CD19_Anti-CD3_Bispecific_Monoclonal_Antibody |
|
| Maps_To |
Blinatumomab |
|
| NCI_Drug_Dictionary_ID |
487684 |
|
| PDQ_Closed_Trial_Search_ID |
487684 |
|
| PDQ_Open_Trial_Search_ID |
487684 |
|
| Preferred_Name |
Blinatumomab |
|
| prefixIRI |
Thesaurus:C62528 |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor |
|
| UMLS_CUI |
C3853839 |
|
| subClassOf |